Cargando…
Brain cortical alterations in COVID-19 patients with neurological symptoms
BACKGROUND: Growing evidence suggests that the central nervous system is affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), since infected patients suffer from acute and long-term neurological sequelae. Nevertheless, it is currently unknown whether the virus affects the brain...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630324/ https://www.ncbi.nlm.nih.gov/pubmed/36340780 http://dx.doi.org/10.3389/fnins.2022.992165 |
_version_ | 1784823577067913216 |
---|---|
author | Sanabria-Diaz, Gretel Etter, Manina Maja Melie-Garcia, Lester Lieb, Johanna M. Psychogios, Marios-Nikos Hutter, Gregor Granziera, Cristina |
author_facet | Sanabria-Diaz, Gretel Etter, Manina Maja Melie-Garcia, Lester Lieb, Johanna M. Psychogios, Marios-Nikos Hutter, Gregor Granziera, Cristina |
author_sort | Sanabria-Diaz, Gretel |
collection | PubMed |
description | BACKGROUND: Growing evidence suggests that the central nervous system is affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), since infected patients suffer from acute and long-term neurological sequelae. Nevertheless, it is currently unknown whether the virus affects the brain cortex. The purpose of this study was to assess the cortical gray matter volume, the cortical thickness, and the cortical surface area in a group of SARS-CoV-2 infected patients with neurological symptoms compared to healthy control subjects. Additionally, we analyzed the cortical features and the association with inflammatory biomarkers in the cerebrospinal fluid (CSF) and plasma. MATERIALS AND METHODS: Thirty-three patients were selected from a prospective cross-sectional study cohort during the ongoing pandemic (August 2020–April 2021) at the university hospitals of Basel and Zurich (Switzerland). The group included patients with different neurological symptom severity (Class I: nearly asymptomatic/mild symptoms, II: moderate symptoms, III: severe symptoms). Thirty-three healthy age and sex-matched subjects that underwent the same MRI protocol served as controls. For each anatomical T1w MPRAGE image, regional cortical gray matter volume, thickness, and surface area were computed with FreeSurfer. Using a linear regression model, cortical measures were compared between groups (patients vs. controls; Class I vs. II–III), with age, sex, MRI magnetic field strength, and total intracranial volume/mean thickness/total surface area as covariates. In a subgroup of patients, the association between cortical features and clinical parameters was assessed using partial correlation adjusting for the same covariates. P-values were corrected using a false discovery rate (FDR). RESULTS: Our findings revealed a lower cortical volume in COVID-19 patients’ orbitofrontal, frontal, and cingulate regions than in controls (p < 0.05). Regional gray matter volume and thickness decreases were negatively associated with CSF total protein levels, the CSF/blood-albumin ratio, and CSF EN-RAGE levels. CONCLUSION: Our data suggest that viral-triggered inflammation leads to neurotoxic damage in some cortical areas during the acute phase of a COVID-19 infection in patients with neurological symptoms. |
format | Online Article Text |
id | pubmed-9630324 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96303242022-11-04 Brain cortical alterations in COVID-19 patients with neurological symptoms Sanabria-Diaz, Gretel Etter, Manina Maja Melie-Garcia, Lester Lieb, Johanna M. Psychogios, Marios-Nikos Hutter, Gregor Granziera, Cristina Front Neurosci Neuroscience BACKGROUND: Growing evidence suggests that the central nervous system is affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), since infected patients suffer from acute and long-term neurological sequelae. Nevertheless, it is currently unknown whether the virus affects the brain cortex. The purpose of this study was to assess the cortical gray matter volume, the cortical thickness, and the cortical surface area in a group of SARS-CoV-2 infected patients with neurological symptoms compared to healthy control subjects. Additionally, we analyzed the cortical features and the association with inflammatory biomarkers in the cerebrospinal fluid (CSF) and plasma. MATERIALS AND METHODS: Thirty-three patients were selected from a prospective cross-sectional study cohort during the ongoing pandemic (August 2020–April 2021) at the university hospitals of Basel and Zurich (Switzerland). The group included patients with different neurological symptom severity (Class I: nearly asymptomatic/mild symptoms, II: moderate symptoms, III: severe symptoms). Thirty-three healthy age and sex-matched subjects that underwent the same MRI protocol served as controls. For each anatomical T1w MPRAGE image, regional cortical gray matter volume, thickness, and surface area were computed with FreeSurfer. Using a linear regression model, cortical measures were compared between groups (patients vs. controls; Class I vs. II–III), with age, sex, MRI magnetic field strength, and total intracranial volume/mean thickness/total surface area as covariates. In a subgroup of patients, the association between cortical features and clinical parameters was assessed using partial correlation adjusting for the same covariates. P-values were corrected using a false discovery rate (FDR). RESULTS: Our findings revealed a lower cortical volume in COVID-19 patients’ orbitofrontal, frontal, and cingulate regions than in controls (p < 0.05). Regional gray matter volume and thickness decreases were negatively associated with CSF total protein levels, the CSF/blood-albumin ratio, and CSF EN-RAGE levels. CONCLUSION: Our data suggest that viral-triggered inflammation leads to neurotoxic damage in some cortical areas during the acute phase of a COVID-19 infection in patients with neurological symptoms. Frontiers Media S.A. 2022-10-20 /pmc/articles/PMC9630324/ /pubmed/36340780 http://dx.doi.org/10.3389/fnins.2022.992165 Text en Copyright © 2022 Sanabria-Diaz, Etter, Melie-Garcia, Lieb, Psychogios, Hutter and Granziera. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Sanabria-Diaz, Gretel Etter, Manina Maja Melie-Garcia, Lester Lieb, Johanna M. Psychogios, Marios-Nikos Hutter, Gregor Granziera, Cristina Brain cortical alterations in COVID-19 patients with neurological symptoms |
title | Brain cortical alterations in COVID-19 patients with neurological symptoms |
title_full | Brain cortical alterations in COVID-19 patients with neurological symptoms |
title_fullStr | Brain cortical alterations in COVID-19 patients with neurological symptoms |
title_full_unstemmed | Brain cortical alterations in COVID-19 patients with neurological symptoms |
title_short | Brain cortical alterations in COVID-19 patients with neurological symptoms |
title_sort | brain cortical alterations in covid-19 patients with neurological symptoms |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630324/ https://www.ncbi.nlm.nih.gov/pubmed/36340780 http://dx.doi.org/10.3389/fnins.2022.992165 |
work_keys_str_mv | AT sanabriadiazgretel braincorticalalterationsincovid19patientswithneurologicalsymptoms AT ettermaninamaja braincorticalalterationsincovid19patientswithneurologicalsymptoms AT meliegarcialester braincorticalalterationsincovid19patientswithneurologicalsymptoms AT liebjohannam braincorticalalterationsincovid19patientswithneurologicalsymptoms AT psychogiosmariosnikos braincorticalalterationsincovid19patientswithneurologicalsymptoms AT huttergregor braincorticalalterationsincovid19patientswithneurologicalsymptoms AT granzieracristina braincorticalalterationsincovid19patientswithneurologicalsymptoms |